Clinical Trials Directory

Trials / Completed

CompletedNCT00203736

A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria

Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
240 (planned)
Sponsor
University of Cape Town · Academic / Other
Sex
All
Age
12 Months
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the efficacy of sulfadoxine-pyrimethamine plus artesunate with that of sulfadoxine-pyrimethamine on its own for the treatment of uncomplicated malaria.

Detailed description

Resistance of Plasmodium falciparum to anti-malarial drugs is a serious impediment to malaria control. In the South East African Combination Anti-malarial Therapy (SEACAT) evaluation, there is an evaluation of the phased introduction of combination anti-malarial therapy (CAT) in Mozambique, Swaziland and South Africa. In order to facilitate formulation of effective regional drug policy and provide a database for decision-making on the implementation of CAT, it is essential that the in vivo response to CAT be investigated. This will be achieved through the SEACAT 01 protocol which is a component of the SEACAT evaluation described in another file on this website. However, in selected Mozambique sites where the intensity of malaria transmission is high, a direct parallel group comparison of monotherapy (SP) with CAT (artesunate, AS, plus SP) will be conducted according to a specific amendment (Amendment 4) to the SEACAT 01 protocol. Amendment 4 is presented in this separate file on the website for clarity.

Conditions

Interventions

TypeNameDescription
DRUGSulfadoxine-pyrimethamine
DRUGArtesunate plus sulfadoxine-pyrimethamine

Timeline

Start date
2003-01-01
Completion
2003-10-01
First posted
2005-09-20
Last updated
2006-11-16

Locations

2 sites across 1 country: Mozambique

Source: ClinicalTrials.gov record NCT00203736. Inclusion in this directory is not an endorsement.